Core Viewpoint - The company plans to repurchase approximately 10.06% equity in its indirect non-wholly owned subsidiary, Changchun Jingyou, for RMB 4.4 million, which will increase its ownership stake to 89.46% after the cancellation of the repurchased shares [1] Group 1: Share Repurchase Details - The repurchase is scheduled to be completed by December 30, 2025 [1] - The repurchased shares will be canceled, leading to an increase in the shareholding percentage of the company in Changchun Jingyou [1] - The board believes that this repurchase is a suitable opportunity to strengthen control and ownership without affecting normal business operations [1] Group 2: Financial Implications - The company expects that the share repurchase will enhance the earnings per share of Changchun Jingyou [1]
精优药业(00858)附属长春精优拟向长春市韩都鼎业房地产策划销售有限公司回购长春精优约10.06%股权